More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Rabbit anti Human SPARC, conjugated with Biotin

Rabbit anti Human SPARC, conjugated with Biotin

Research Use Only
X2745P
Nordic-MUbio
ApplicationsImmunoHistoChemistry
DownloadDatasheet
Product group Antibodies
ReactivityHuman
Price on request
50 ug
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    Nordic-MUbio
  • Product Name
    Rabbit anti Human SPARC, conjugated with Biotin
  • Delivery Days Customer
    7
  • Applications
    ImmunoHistoChemistry
  • Applications Supplier
    Immunohistochemistry
  • Category Supplier
    Primary antibodies
  • Certification
    Research Use Only
  • Concentration
    See vial for concentration
  • Host
    Rabbit
  • Scientific Description
    Secreted Protein Acidic and Rich in Cysteine, SPARC, SPARC-related modular calcium-binding protein 2 [Precursor], Secreted modular calcium-binding protein 2, SMOC-2, Smooth muscle-associated protein 2, SMAP-2
  • Shelf life instruction
    See expiration date on vial
  • Reactivity
    Human
  • Reactivity Supplier
    Human SPARC;may cross react with SPARCL1
  • Reactivity Supplier Note
    Synthetic peptide derived from the human SPARC protein.
  • Storage Instruction
    Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles
  • UNSPSC
    12352203

References

  • 1. Shi Q, et al. 'Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.' Oncogene. 2007 Jan 8; [Epub ahead of print] PMID: 17213807 2. Aouacheria A, et al. 'In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions.' BMC Genomics. 2007 Jan 3;8(1):2 [Epub ahead of print] PMID: 17201911 3. Xue LY, et al. 'Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma.' BMC Cancer. 2006 Dec 22;6(1):296 [Epub ahead of print] PMID: 17187659 4. Arp HP, et al. 'Predicting the partitioning behavior of various highly fluorinated compounds.' Environ Sci Technol. 2006 Dec 1;40(23):7298-304. PMID: 17180981 5. Kelly KA, et al. 'SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration.' J Leukoc Biol. 2006 Dec 18; [Epub ahead of print] 6. Markovic, S., et al. 'Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.' J. Clin. Oncol. 2010, Vol. 28, No. 15, 8578 7. Weiss, G.J., et al. 'Molecular characterization of interdigitating dendritic cell sarcoma.' Rare Tumors, 2010, 2:e50 8. Alonso, E.N., et al. ‘Genes Related to Suppression of Malignant Phenotype Induced by Maitake D-Fraction in Breast Cancer Cells.’ J. Med. Food., 16, 602-617 (2013).